Turmoil in the financial markets is having a disproportionate impact on biotech – and coupled with extra caution from regulators, is threatening innovation.

Biotechnology and risk have always been synonymous. But now those risks are evolving and growing, exposing companies to fresh hazards.

UK biotech Phynova makes a business out of developing traditional medicines, but when it comes to raising money it is pioneering a new, low-cost route to American investors.

The UK biotech sector has fallen victim to the mayhem in the capital markets. After a year of falling share prices, five quoted companies have put up “for sale” signs.

Corporate incubators bridge the seed funding gap, but apart from pocket money what can start-ups learn from their foster parents?

The European Commission has selected six areas of pioneering research for its long-awaited lead markets initiative.